missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human IL-33 Recombinant Protein
E. coli Recombinant Protein
243.00 € - 2870.00 €
Spezifikation
Zugriffsnummer | O95760 |
---|---|
Konzentration | 200 μg/mL |
Zur Verwendung mit (Anwendung) | Control, ELISA, Western Blot |
Zusammensetzung | PBS with 1 mM EDTA, 2 mM DTT and no preservative; pH 7.2 |
Gen-ID (Entrez) | 90865 |
Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
---|---|---|---|---|---|---|---|---|---|
Produktcode | Marke | Menge | Preis | Menge & Verfügbarkeit | |||||
17666625
|
Invitrogen™
RP87832 |
10 μg |
243.00 €
10 Mikrogramm |
Verfügbar ab: 27-05-2024 Loggen Sie sich ein, um den Lagerbestand zu sehen |
Bitte melden Sie sich an, um diesen Artikel zu kaufen. Sie benötigen ein Web-Konto? Registrieren Sie sich noch heute! | ||||
17676625
|
Invitrogen™
RP87833 |
25 μg |
428.00 €
25 Mikrogramm |
Verfügbar ab: 27-05-2024 Loggen Sie sich ein, um den Lagerbestand zu sehen |
Bitte melden Sie sich an, um diesen Artikel zu kaufen. Sie benötigen ein Web-Konto? Registrieren Sie sich noch heute! | ||||
17686625
|
Invitrogen™
RP87834 |
100 μg |
1122.00 €
100 Mikrogramm |
Verfügbar ab: 27-05-2024 Loggen Sie sich ein, um den Lagerbestand zu sehen |
Bitte melden Sie sich an, um diesen Artikel zu kaufen. Sie benötigen ein Web-Konto? Registrieren Sie sich noch heute! | ||||
17696625
|
Invitrogen™
RP87835 |
500 μg |
2870.00 €
500 Mikrogramm |
Verfügbar ab: 27-05-2024 Loggen Sie sich ein, um den Lagerbestand zu sehen |
Bitte melden Sie sich an, um diesen Artikel zu kaufen. Sie benötigen ein Web-Konto? Registrieren Sie sich noch heute! | ||||
Beschreibung
IL-33 (Interleukin-33) is a 270 amino acid, highly divergent protein belonging to the IL-1 family with an IL-1-like C-terminal domain. IL-33 is a dual function protein that may function both as a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties. IL-33 binds to and signals through IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6. IL-33 activates NF-kappaB and MAP kinases, and drives production of TH2-associated cytokines from in vitro polarized TH2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. IL-33 is proteolytically converted to a mature form by CASP1 and is highly expressed in high endothelial venules found in tonsils, Peyer's patches and mesenteric lymph nodes and is almost undetectable in placenta. Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine. Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties. Despite its predicted molecular weight, IL-33 will often run at higher molecular weight in SDS-PAGE. Studies have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine, and an intracellular nuclear factor with transcriptional regulatory properties.Spezifikation
O95760 | |
Control, ELISA, Western Blot | |
90865 | |
Human IL-33 (aa 112-270) | |
-20°C | |
0.01 ng/ μg cytokine | |
IL33 | |
Unconjugated | |
Liquid |
200 μg/mL | |
PBS with 1 mM EDTA, 2 mM DTT and no preservative; pH 7.2 | |
18 kD | |
E. coli | |
RUO | |
9230117N10Rik; C9orf26; DVS27; DVS27-related protein; H-IL-33; Il1f11; IL-1F11; Il33; IL-33; ILN; Interleukin; interleukin 33; Interleukin-1 family member 11; Interleukin33; Interleukin-33; Interleukin-33 (109-270); Interleukin-33 (95-270); Interleukin-33 (99-270); Interleukin-33(102-266); Interleukin-33(109-266); NFEHEV; NFHEV; NF-HEV; nuclear factor for high endothelial venules; nuclear factor from high endothelial venules; RGD1311155; RP11-575C20.2 | |
Human | |
Recombinant | |
>95% |